Clinical Trial Detail

NCT ID NCT02927340
Title A Study of Lorlatinib in Advanced ALK and ROS1 Rearranged Lung Cancer With CNS Metastasis in the Absence of Measurable Extracranial Lesions
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements yes
Sponsors Massachusetts General Hospital
Indications

non-small cell lung carcinoma

Therapies

Lorlatinib

Age Groups: adult senior

Additional content available in CKB BOOST